NTLA
Intellia Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | +1 | 344.29K | $4.16M | +1 | −1 |
| Q2 2026 | 107 | +3 | 103.07M | $1.74B | +8 | −6 |
| Q1 2026 | 108 | +4 | 82.71M | $1.06B | +13 | −9 |
| Q4 2025 | 104 | -1 | 82.78M | $744.21M | +1 | −2 |
| Q3 2025 | 18 | +2 | 59.30M | $1.02B | +2 | −1 |
| Q2 2025 | 14 | +2 | 47.63M | $446.74M | +2 | n/a |
| Q1 2025 | 9 | -4 | 25.51M | $181.35M | n/a | −4 |
| Q4 2024 | 13 | +3 | 26.17M | $305.16M | +3 | n/a |
| Q3 2024 | 9 | 0 | 18.08M | $371.64M | +1 | −1 |
| Q2 2024 | 9 | n/a | 17.86M | $399.79M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 11.60M | n/a | $259.51M | 2.3% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 2.29M | n/a | $51.35M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | T. Rowe Price ✦ | 1.24M | n/a | $27.86M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Two Sigma Investments ✦ | 829.28K | n/a | $18.56M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 781.77K | n/a | $17.50M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 6 | Citadel Advisors ✦ | 762.68K | n/a | $17.07M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | Norges Bank ✦ (passive) | 240.41K | n/a | $5.38M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Millennium Management ✦ | 75.67K | n/a | $1.69M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 38.70K | n/a | $866,106 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 22.80K shares, $292 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.86K sh · $23,170
Officer, Director · 2.79K sh · $36,205
Officer, Director · 19.89K sh · $250,614
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology